COVARIS welcomes conversations with pharmaceutical and biotech sponsors, CROs, clinical development teams, trial operations leaders, medical and evidence-generation functions, and scientific collaborators.

A first conversation is most useful when there is a clearly defined question about trial footprint, study timing, disease-relevant external context, or selected participant and assessment settings.

Useful context to include:

• indication or disease area
• development stage
• planned countries or regions
• expected enrollment, study or assessment window
• relevant endpoint or assessment context
• the decision or question the analysis should support